The Impact of Non-Adherence to Antihypertensive Drug Therapy

Medication non-adherence is a major healthcare barrier, especially among diseases that are largely asymptomatic, such as hypertension. The impact of poor medication adherence ranges from patient-specific adverse health outcomes to broader strains on health care system resources. The Centers for Dise...

Full description

Bibliographic Details
Main Authors: Syed Karam Mustafa Gardezi, William W. Aitken, Mohammad Hashim Jilani
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Healthcare
Subjects:
Online Access:https://www.mdpi.com/2227-9032/11/22/2979
_version_ 1797459107326722048
author Syed Karam Mustafa Gardezi
William W. Aitken
Mohammad Hashim Jilani
author_facet Syed Karam Mustafa Gardezi
William W. Aitken
Mohammad Hashim Jilani
author_sort Syed Karam Mustafa Gardezi
collection DOAJ
description Medication non-adherence is a major healthcare barrier, especially among diseases that are largely asymptomatic, such as hypertension. The impact of poor medication adherence ranges from patient-specific adverse health outcomes to broader strains on health care system resources. The Centers for Disease Control (CDC) Wide-ranging Online Data for Epidemiologic Research (WONDER) database was used to retrieve Centers for Medicare and Medicaid Services’ data pertaining to blood pressure (BP) medication adherence, socio-economic variables, and cardiovascular (CV) outcomes across the United States. Multivariable linear regression models were used to estimate the change in total CV deaths as a function of non-adherence to BP medications. For every percent increase in the non-adherence rate, the total number of CV deaths increased by 7.13 deaths per 100,000 adults (95% CI: 6.34–7.92), even after controlling for the percentage of residents with access to insurance, the percentage of residents who were eligible for Medicaid, the percentage of residents without a college education, median home value, income inequality, and the poverty rate (<i>p</i> < 0.001). There is a significant association between non-adherence to BP medications and total CV deaths. Even a one percent increase in the adherence rate in the United States could result in tens of thousands of preventable CV deaths. Based on recently published CDC data, this could also have a tremendous impact on health care costs. This provides compelling evidence for increased efforts to improve adherence.
first_indexed 2024-03-09T16:47:38Z
format Article
id doaj.art-25d67d6574474102991c7a51e0dc8f14
institution Directory Open Access Journal
issn 2227-9032
language English
last_indexed 2024-03-09T16:47:38Z
publishDate 2023-11-01
publisher MDPI AG
record_format Article
series Healthcare
spelling doaj.art-25d67d6574474102991c7a51e0dc8f142023-11-24T14:44:53ZengMDPI AGHealthcare2227-90322023-11-011122297910.3390/healthcare11222979The Impact of Non-Adherence to Antihypertensive Drug TherapySyed Karam Mustafa Gardezi0William W. Aitken1Mohammad Hashim Jilani2TJ Samson Community Hospital, Glasgow, KY 42141, USADepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USADivision of Cardiovascular Health, University of Cincinnati Medical Center, Cincinnati, OH 45219, USAMedication non-adherence is a major healthcare barrier, especially among diseases that are largely asymptomatic, such as hypertension. The impact of poor medication adherence ranges from patient-specific adverse health outcomes to broader strains on health care system resources. The Centers for Disease Control (CDC) Wide-ranging Online Data for Epidemiologic Research (WONDER) database was used to retrieve Centers for Medicare and Medicaid Services’ data pertaining to blood pressure (BP) medication adherence, socio-economic variables, and cardiovascular (CV) outcomes across the United States. Multivariable linear regression models were used to estimate the change in total CV deaths as a function of non-adherence to BP medications. For every percent increase in the non-adherence rate, the total number of CV deaths increased by 7.13 deaths per 100,000 adults (95% CI: 6.34–7.92), even after controlling for the percentage of residents with access to insurance, the percentage of residents who were eligible for Medicaid, the percentage of residents without a college education, median home value, income inequality, and the poverty rate (<i>p</i> < 0.001). There is a significant association between non-adherence to BP medications and total CV deaths. Even a one percent increase in the adherence rate in the United States could result in tens of thousands of preventable CV deaths. Based on recently published CDC data, this could also have a tremendous impact on health care costs. This provides compelling evidence for increased efforts to improve adherence.https://www.mdpi.com/2227-9032/11/22/2979non-adherencecardiovascular diseasehypertensionmortality
spellingShingle Syed Karam Mustafa Gardezi
William W. Aitken
Mohammad Hashim Jilani
The Impact of Non-Adherence to Antihypertensive Drug Therapy
Healthcare
non-adherence
cardiovascular disease
hypertension
mortality
title The Impact of Non-Adherence to Antihypertensive Drug Therapy
title_full The Impact of Non-Adherence to Antihypertensive Drug Therapy
title_fullStr The Impact of Non-Adherence to Antihypertensive Drug Therapy
title_full_unstemmed The Impact of Non-Adherence to Antihypertensive Drug Therapy
title_short The Impact of Non-Adherence to Antihypertensive Drug Therapy
title_sort impact of non adherence to antihypertensive drug therapy
topic non-adherence
cardiovascular disease
hypertension
mortality
url https://www.mdpi.com/2227-9032/11/22/2979
work_keys_str_mv AT syedkarammustafagardezi theimpactofnonadherencetoantihypertensivedrugtherapy
AT williamwaitken theimpactofnonadherencetoantihypertensivedrugtherapy
AT mohammadhashimjilani theimpactofnonadherencetoantihypertensivedrugtherapy
AT syedkarammustafagardezi impactofnonadherencetoantihypertensivedrugtherapy
AT williamwaitken impactofnonadherencetoantihypertensivedrugtherapy
AT mohammadhashimjilani impactofnonadherencetoantihypertensivedrugtherapy